THE ONLY BIOLOGIC INDICATED FOR
OCS-DEPENDENT ASTHMA

More asthma patients stopped using OCS with DUPIXENT, regardless of baseline EOS levels1,2,a-c

OCS dose reduction at Week 24 (primary endpoint)
NO BIOMARKER REQUIREMENT (ITT POPULATION) Trial 3
86%
OF PATIENTS REDUCED
OR ELIMINATED THEIR
OCS DOSE

with DUPIXENT 300 mg + SOC (n=103)
vs 68% with placebo + SOC (n=107)

52%
OF PATIENTS COMPLETELY
ELIMINATED OCS USE

with DUPIXENT 300 mg + SOC (n=103)
vs 29% with placebo + SOC (n=107)

  • Effects on oral steroid reduction were similar irrespective of baseline blood eosinophil levels

Reduced severe exacerbation rates and improved lung function at Week 24 in the ITT population (secondary endpoints)1,2,a-d

  • 59% reduction in annualized rate of severe exacerbations with DUPIXENT 300 mg + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63])
  • 220 mL improvement in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL])
  • a ITT population was unrestricted by minimum baseline eosinophils or other Type 2 biomarkers (eg, FeNO or IgE).2
  • b The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.1
  • c For inclusion in the study, all patients were required to be on daily OCS in addition to regular use of standard of care of high-dose ICS plus an additional controller medication; subjects with baseline blood eosinophil levels >1500 cells/μL (<1.3%) were excluded.1
  • d Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.1

See an OCS-dependent patient appropriate for DUPIXENT

VIEW PATIENT

References:

  1. DUPIXENT Prescribing Information.
  2. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.